SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-039715
Filing Date
2022-03-30
Accepted
2022-03-30 08:00:11
Documents
9
Period of Report
2022-05-12

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm223491-1_def14a.htm DEF 14A 1313547
2 GRAPHIC lg_rubiustherapeut-4c.jpg GRAPHIC 200208
3 GRAPHIC sg_pablocagnoni-bw.jpg GRAPHIC 6899
4 GRAPHIC tm223491d1-pc_ceoneo4c.jpg GRAPHIC 34465
5 GRAPHIC tm223491d1-pc_quarterly4clr.jpg GRAPHIC 37395
6 GRAPHIC tm223491d1-fc_perform4c.jpg GRAPHIC 109687
7 GRAPHIC tm223491d1-fc_compens4clr.jpg GRAPHIC 53451
8 GRAPHIC tm223491d1-px_page01bw.jpg GRAPHIC 817517
9 GRAPHIC tm223491d1-px_page02bw.jpg GRAPHIC 841272
  Complete submission text file 0001104659-22-039715.txt   4183944
Mailing Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

IRS No.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38586 | Film No.: 22783209
SIC: 2836 Biological Products, (No Diagnostic Substances)